SMFR SEMA4 HLDGS CORP

Sema4 Achieves HITRUST CSF Certification

Sema4 Achieves HITRUST CSF Certification

HITRUST CSF Certification validates Sema4’s commitment to meeting key healthcare regulations and protecting sensitive information

STAMFORD, Conn., April 06, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that its health intelligence platform, Centrellis®, has earned Certified status for information security by the Health Information Trust (HITRUST) Alliance.

HITRUST CSF (Common Security Framework) Certified status demonstrates that Sema4’s Centrellis platform has met industry-defined health information security requirements and is appropriately managing risk. This achievement places Sema4 in an elite group of organizations worldwide that have earned this certification.

“We are pleased to receive this prestigious certification from HITRUST, which further underscores our commitment to the highest possible levels of data security and privacy and to treating patients as partners,” said , PhD, Chief Data Officer, Sema4. “We will continue to prioritize the utilization of best-in-class tools and systems to safeguard all patient information and other data as we accelerate our mission of transforming healthcare.”

Sema4’s Centrellis integrated health information platform is one of the largest and fastest growing in existence, providing data-driven insights to enable personalized medicine. It has approximately 12 million de-identified clinical records, including more than 500,000 with genomic profiles. As one of the most sophisticated systems in the world, the data-driven insights from the Centrellis platform offer health system partners, clinicians, and patients a more complete understanding of disease and wellness.

“The HITRUST Assurance Program is the most rigorous available, consisting of a multitude of quality assurance checks, both automated and manual,” said Bimal Sheth, Executive Vice President, Standards Development & Assurance Operations, HITRUST. “The fact that Sema4 has achieved HITRUST Risk-based, 2-year Certification attests to the high quality of their information risk management and compliance program.”

About Sema4

Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Centrellis®, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.

For more information, please visit sema4.com and connect with Sema4 on , , and .

Media Contact:

Radley Moss



EN
06/04/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SEMA4 HLDGS CORP

 PRESS RELEASE

GeneDx to Report Second Quarter 2024 Financial Results on Tuesday, Jul...

GeneDx to Report Second Quarter 2024 Financial Results on Tuesday, July 30, 2024  STAMFORD, Conn., July 11, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the second quarter of 2024 after the market closes on Tuesday, July 30, 2024. Management will host a conference call that day to discuss second quarter 2024 financial and operating results at 4:30 p.m. Eastern Time.  Conference Call Details Investors interested in listening to the conference call are required ...

 PRESS RELEASE

GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapi...

GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing (rWGS) Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients -- New integration to streamline access for health systems and improve provider and patient journeys using Epic for electronic connections -- -- Increases commercial footprint and focus on accelerating utilization of rWGS services in neonatal intensive care units (NICUs) -- STAMFORD, Conn., June 10, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insig...

 PRESS RELEASE

GeneDx Announces Patient Access Program to Expand Access to Exome Test...

GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the first-of-its-kind patient access program, developed in partnership with leading biopharma companies, which aims to increase access to exome sequencing for pediatric epilepsy patients. “Receiving a genetic diagnosis can be critical in a child’s journey toward effective treatment and care, and we are thrilled our biopha...

 PRESS RELEASE

GeneDx to Participate in Upcoming Investor Conferences

GeneDx to Participate in Upcoming Investor Conferences STAMFORD, Conn., May 22, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in two upcoming investor conferences in June: Jefferies Healthcare Conference - New York City, New York Fireside chat on Wednesday, June 5 at 9:00 a.m. ET44th Annual Goldman Sachs Global Healthcare Conference - Miami, Florida Fireside chat on Monday, June 10 at 3:20 p.m. ET Live and archived webcasts of the presentation will be avail...

 PRESS RELEASE

GeneDx Reports First Quarter 2024 Financial Results and Business Highl...

GeneDx Reports First Quarter 2024 Financial Results and Business Highlights Reported first quarter 2024 revenue from continuing operations1 of $61.5M with 96% year-over-year growth of exome and genome test revenue Expanded first quarter 2024 adjusted gross margins2 from continuing operations to 61% Narrowed first quarter 2024 adjusted net loss2 to $8.5M and delivered 71% year-over-year cash burn reduction Raised guidance to deliver between $235M and $245M in FY 2024 revenue and reiterate path to profitability in 2025 GeneDx to host conference call today at 4:30 p.m. ET STAMF...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch